Accepting patients
QUINTESSENTIAL-2
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma
- CAR T Cell
- GPRC5D
- Randomization
- Phase 3
- 188466
Accepting patients
MajesTEC-7
A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
- Has results
- Myeloma Service
- 193667
Accepting patients
Sonrotoclax (BGB-11417)
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- BCL-2 Inhibitor
- Phase 1/2
- Has results
- Myeloma Service
- 152032
- CAR T Cell
- BCMA
- CD19
- Phase 1/2
- Has results
- 198557
Accepting patients
DURGA-4
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- CAR T Cell
- CD19
- BCMA
- Randomization
- Phase 3
- 200822
Accepting patients
TRIlogy-4
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody
- T Cell Engager (TCE)
- Trispecific Antibody
- BCMA
- CD3
- GPRC5D
- Randomization
- Phase 3
- 200091
Accepting patients
Belantamab Mafodotin Combination Therapy
A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma
- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 1/2
- Myeloma Service
Accepting patients
LP-118
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory NHL, RT, MM, T-PLL, Acute Leukemia (AML, ALL), MDS, MDS/MPN, and MF
- BCL-2 Inhibitor
- Bcl/xL Inhibitor
- Phase 1
- 148736
Accepting patients
UltraFrailMM
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma: A Phase 2 Multicenter Study
- Monoclonal Antibody
- CD38
- Phase 2
- 171326
- CELMoD
- Expanded Access
- 202123
4 hidden based on your filters.Show All